World Congress on Drug Discovery and Drug Design September 11-12, 2019 Singapore

After successful conference in 2018, Conference Series llc Ltd is very delighted to invite you all to the "World Congress on Drug Discovery and Drug Design " (Drug Discovery Congress 2019) scheduled on September 11-12, 2019 at Singapore. We are progressively working for the initiation of new world, perspectives and views in the field of Drug Discovery. Conference Series llc Ltd is providing a great platform for thousands of Drug Discovery meet, learn, share and exchange views. We are concentrating on a view that everyone should gain from the conference. So, we are organizing plenary sessions, poster exhibitions and section programs, workshops at the conference.

Drug Discovery Congress 2019 is supported with related journals and their editorial board members which provide a chance of meeting them, along with experts in Medicine, Drug Target Discovery and Pharmaceutical sciences.

Drug Discovery Congress 2019 will be a great event where experts from universities, top Pharmaceutical industries, research centers and from the societies and association related to Pharmaceuticals gather and share their insights. So, all are whole heartedly invited to be a part of this conference.

Drug Discovery Congress 2019 Highlights:

• 150+ Participation (70% Industry: 30% Academia)
• 5+ Keynote Speakers
• 30+ Plenary Speakers
• 3+ Exhibitors
• 20+ Innovative Educational Sessions
• B2B Meetings

Exhibition

Why exhibit:

• Make sales
• Debut new products
• Profile your brand
• Meet new business partners and suppliers
• Develop key relationships
• Educate healthcare, pharma and biotech institutions and academia

Why you should attend:

The DRUG DISCOVERY CONGRESS 2019 anticipates participants, renowned speakers and eminent delegates across the globe to be attending the conference to share their valuable presentation and galvanize the scientific community. Scientific people from all over the globe focused on learning about emerging technologies about Drug Discovery and Advanced Drug Design Technology. This is a best globalized opportunity to reach the largest assemblage of participants from the scientific community and research. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug research developments, and receive name recognition at this 2-days event. World renowned speakers and the most recent techniques, developments, the newest updates in Drug Discovery are hallmarks of this conference.

Track 1: Drug Designing

Drug design is an inventive process of medication discovered by biological target. It is also known as rational drug design or rational design. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense. Drug design relies on the knowledge of the three-dimensional structure of bimolecular targets. The drug is an organic molecule, when it is predicament to target site it can either inhibit or activate the function of a biomolecule which effects in therapeutic benefit.

Related Conferences:

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 2: Drug Target Discovery

The term drug targets regularly used in medicinal research to describe the native protein in the body whose activity is modified by a drug resulting in a distinct effect, which may be a desirable therapeutic effect or an unwanted side effect. In this context, the biological target is often referred to as a biological target. The most common drug targets are G-protein couple receptor, enzymes, ligand gated channels, voltage gated channels, ion channels, nuclear hormone receptor and membrane transport proteins.

Related Conferences:

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 3: Computer Aided Drug Design-CADD

Computer aided drug design and Advanced Instrumentation is that the most basic goal is to predict whether a given bioactive molecule can bind to a target or not. Study in drug design or biomarkers in drug design measures the conformation of the little molecule and to model conformational changes within the biological target which will occur once the little molecule binds thereto. Recent advances in CADD with the utilization of high performance computing technology and Insilco molecular design computer code and tools offer might optimize the parameters for the molecular mechanics calculations and additionally provide an estimation of the electronic properties (electrostatic potential, polarizability, etc.) of the drug molecule that may influence binding affinity within the use of ultrasound in medicinal chemistry. High-resolution 1H-NMR chemical analysis and X-Ray absorption chemical analysis ways may additionally be accustomed offer semi-quantitative prediction of the required affinity

Related Conferences:

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 4: Pharmaceutical Drug Discovery and Nanotechnology

Nanotechnology has now introduced to develop medicine. Nanotechnology contains the use of materials with essential length scales in the nanometer measurement which demonstrate significantly changed properties associated to micron structured materials. Such materials can include particles, fibers, grain sizes, etc. This session highlighted the progressions nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment, an but not limited to) drug delivery, tissue engineering, transplants, sensors, cancer treatment, and toxic

Related Conferences:

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 5: Novel Drug Target Approaches

Categorizing drug targets plays crucial roles in designing new drugs and opposing diseases. Unfortunately, our current understanding about drug targets is far from complete. Screening drug targets in the lab is an expensive and time-consuming procedure. In the past decade, the accumulation of various types of study of science related data makes it possible to develop computational approaches to predict drug targets. Non-communicable diseases such as cancer, atherosclerosis and diabetes are responsible for most important social and health disorder as millions of people are dying every year. Out of which, atherosclerosis is the leading cause of deaths globally. The lipid irregularity is one of the most important adjustable risk factors for atherosclerosis. Both genetic and conservation components are associated with the development of atherosclerotic signs

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 6: Pharmacovigilance

Pharmacovigilance is that branch of pharmacology that focuses on analysis, detection and prevention of adverse effects caused by pharmaceutics. Adverse drug reactions (ADRs) are a major cause of patient related morbidity and mortality. Reporting of ADRs is considered to be an important step in maintaining and achieving a safe drug therapy use. Nowadays, Pharmacovigilance hugely emphasizes on challenges like Mass treatment regimens, Un-labelled and Off-labelled indications, Nutritional aspects, New drugs, Adherence, Co-morbidities and Drug resistances. Medication errors such as misuse, overdose, abuse of a drug and drug exposure are some of the reasons responsible for ADRs. The main objective is to generate independent, evidence-based recommendations on the safety of medicines and to monitor benefit-risk profile of different pharmaceutics.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 7: Proteomics & Bioinformatics in Drug Discovery

Proteomics, the large-scale analysis of proteins, contributes expressively to our understanding of gene function in the post-genomic era. Proteomics can be divided into three main areas: (1) protein micro-characterization for large-scale certification of proteins and their post-translational changes; (2) 'differential display' proteomics for comparison of protein levels with potential application in a extensive range of diseases; and (3) studies of protein–protein interactions using methods such as mass spectrometry or the yeast two-hybrid system. Proteomics technologies are under nonstop progresses and new skills are introduced. Nowadays high quantity acquisition of proteome data is possible.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 8: Biomarkers in Drug Design

The discovery and evaluation of any novel biomarkers will ideally be specialized to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, so as to ensure accuracy and reproducibility of laboratory procedures. Predictive biomarkers indicate the likelihood of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers include both tumor-specific and surrogate biomarkers, and are crucial to accelerating the drug development process

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 9:  Drug Design And Development

Drug design is the method of inventing innovative medications. Drug design defines the design of molecules that are corresponding in shape and charge to the bio molecular target with which they interact and therefore will bind to it. Generally, the drug is a tiny organic molecule which triggers or slows down the activity of a bio-molecule such as a protein which repeatedly results in a medicinal benefit to the patient. Discovery of drugs is challenging. Various medications are invented by chance observations, the scientific examination of other medicines or by finding out the side effects of some other drugs. A methodical technique is significant screening observations where important drug targets are tested with thousands of various compounds to observe, whether conversations occur. Basically, drug design involves design of small molecules that are harmonizing in shape and charge to the bio molecular target to which they act together and consequently will bind to it.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 10: Clinical Trails and Biotherapeutics

Clinical Biotherapeutic aspects including study drug design, drug-drug interactions, QT assessment, immunogenicity, comparability, special populations (hepatic and liver failure), PK and PD, regulatory expectations of PK and PD characterization, as well as reviewing factors which influence the ADME of Biotherapeutics. The objectives of early clinical development of therapeutic proteins are the same as for small molecules i.e. to investigate the molecule in a manner that will gain necessary knowledge about its tolerability safety pharmacokinetics (PK) and if possible pharmacodynamics (PD) effects in the most appropriate human populations while simultaneously protecting their safety. However, there are specific features of proteins that must be considered when designing clinical pharmacology studies.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 11:  Pharmaceutical Research and Development

In revelation process incorporates the early periods of research, which are intended to recognize a drug and perform essential tests in the lab. This initially phase of the procedure takes around three to six years. Before the end, scientists plan to distinguish a promising medication competitor to additionally think about in the lab and in creature models, and afterward in individuals. These advances offer extraordinary guarantee, yet additionally add unpredictability to the Research and development process. With a specific end goal to guarantee the wellbeing and viability of customized treatments that are utilized close by diagnostics, clinical trial conventions must be adjusted and upgraded. This may require the utilization of extra systems and assets, and in addition new or creative types of information accumulation. In addition, by their extremely nature, the patient populace distinguished to react to focused treatments is smaller, which makes tolerant enrolment more troublesome.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 12:  Medicinal Chemistry in Drug Discovery

The modern drug discovery process is an overview to the development of new drugs. Now a days new biological targets, methodologies and advanced computing have enhanced modern drug discovery and have given medicinal chemistry a more thoughtful skill set and toolkit to hold the nuances  of disease pathophysiology. The medicinal chemistry related methodologies and a methodology in drug discovery improves the efficiency   in drug discovery and lessening attrition. In drug designing, structure-based drug design, and fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 13: Innovative Drug Discovery and Nanotechnology

Nanotechnology, a multidisciplinary logical endeavor, includes creation and use of materials, gadgets or frameworks on the nanometer scale. The field of nanotechnology is as of now experiencing hazardous improvement on many fronts. The innovation is required to make developments and assume a basic part in different biomedical applications, in drug delivery, as well as in atomic imaging, biomarkers and biosensors. Target-specific drug therapy and strategies for early finding of pathologies are the need look into territories where nanotechnology would assume a crucial part. Diverse nanotechnology-based drug delivery and imaging approaches and their monetary effect assume fundamental part in pharmaceutical and biomedical enterprises.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 14: Advancements in Drug Metabolism

Drug metabolism is the procedure by which the body separates and changes over prescription into dynamic concoction substances. It is the enzymatic transformation of one concoction compound into another. Drugs can be utilized by oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization; whatever the procedure, the objective is to make the drug less demanding to discharge. The proteins engaged with metabolism are available in many tissues however for the most part are more moved in the liver. Drug metabolism rates shift among patients. A few patients use a drug so quickly that therapeutically compelling blood and tissue focuses are not come to; in others, metabolism might be slow to the point that standard dosages have dangerous impacts. Singular drug metabolism rates are affected by hereditary factors, existing together disorders (especially unending liver disorders and propelled heart disappointment), and drug connections (particularly those including acceptance or restraint of metabolism). By and large, metabolic procedures will change over the drug into a more water-dissolvable compound by expanding its extremity.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

Track 15: Chemoinformatic Drug Discovery

Chemoinformatic plays a vital link between made-up design and in drug design through mining of information from the data and translate into knowledge. Derivation of information and knowledge is only one aspect of chemoinformatic. The use of consequent knowledge in a design and selection support role is an important part of the drug design cycle. The main processes within drug discovery are lead documentation, where a lead is something that has activity in the low micro molar range, and lead optimization, which is the process of transforming a lead into a drug candidate. Chemo informatics methods can be used proactively to designing and filter the most appropriate compounds to work within the real world.

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

 Track 16:Novel Drug Delivery System in pharmaceutics

The process by which a drug is distributed can have an important effect on its efficacy Some drugs have an optimum concentration range within which extreme benefit is derived, and concentrations above or below this range can be noxious or produce no therapeutic benefit at all. On the other hand, the very slow improvement in the efficacy of the treatment of severe diseases, has optional a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues. These nanoparticles would be loaded with drugs and plagued to specific parts of the body where there is completely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to extend, localize, target and have a vulnerable drug interaction with the diseased muscle

5^th World Congress on Natural Products, Medicinal Plants and Traditional Medicines November 5-6, 2018 at Singapore; 13 ^th World Congress on Pharmacology and Toxicology November 14-15, 2018 Melbourne, Australia; 6 ^th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th Asia-Pacific Pharma Congress April 22-24, 2019 Tokyo, Japan; 28^th European Congress on Clinical Microbiology Conference during April 21- 24 2018 at Madrid, Spain; 53^rd American Society of Health Clinical Meeting and Exhibition, December 02-06 2018 at Anaheim, USA; 2^nd Clinical Trial Financial Management Summit during April 05-06 2018, at Philadelphia, USA; Congress on Drug Discovery and Therapy, July 09-12, 2018 at Boston, USA.

Related Associations or Societies:

Drug Information Association, Kuwait Pharmaceutical Association, Malaysian Pharmaceutical Society, Maryland Pharmacists Association (MPhA), Pharmaceutical Society of Australia, The Pharmacy Guild of Australia, The Society of Hospital Pharmacists of Australia, Chinese Pharmaceutical Association, American Association of Colleges of Pharmacy (AACP), American Pharmacists Association (APhA), American Society for Pharmacy Law American Society of Consultant Pharmacists (ASCP),European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union  (EPU), Pharmaceutical Group of the European Union (PGEU), Norwegian Pharmacy Association.

The global drug discovery informatics market is projected to reach USD 2.84 Billion in 2022 from USD 1.50 Billion in 2016, at CAGR of 11.2% during forecast period. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. In the current market scenario, there is a growing demand for discovery informatics solutions. The major factors driving the growth of the drug discovery informatics market include the rising R&D expenditure, the increasing focus on drug discovery, and need to control the drug discovery and development cost. On the other hand, the scarcity of skilled professionals, and high pricing and setup cost of informatics software are the major factors restraining the growth of this market. The key players operating in the drug discovery informatics market are IBM, Infosys , Schrödinger, PerkinElmer, and Thermo Fisher Scientific .

Report Includes:

This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.

With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

In Singapore

Singapore is a key drug market for Western pharmaceutical companies. Singapore’s pharmaceutical market is currently estimated to be about $820 million. It is expected to grow at a steady rate of 6% in 2017, compared to the 5% average growth in the Asia-Pacific region. Singapore has also emerged as one of the most integrated and advanced hubs for pharmaceutical manufacturing and research in Southeast Asia. The country’s healthcare system was ranked second in the world by the Bloomberg Healthcare Efficiency Index in 2014, only behind Hong Kong. Singapore’s pharmaceutical industry is regulated by the Health Sciences Authority (HSA) and the Health Products Act 2007, which includes all medical devices, pharmaceuticals, medicines and other supplements.

The Asia Pacific drug discovery market in 2016 was worth $6224 million. The market is expected to reach $13462 million by 2024 at a CAGR of 10.1% between 2016 and 2024. Aging population rise in healthcare spending and increase in lifestyle-oriented diseases and fatalities are some of the factors driving the drug discovery market in the Asia pacific region.

Market Insights

The drug discovery market by technology is segmented into QPCR, DNA Microarrays, Protein Microarrays, High–throughput screening, mass spectrometer, GEL Electrophoresis, Chromatograph, Protein and Nucleic Acid Isolation and other technologies.

The countries analyzed in the Asia Pacific drug discovery market are India, China, Japan, Korea, Australia and rest of Asia Pacific. The entry of new companies in the market and substitute products acts as a threat to the Asia pacific drug discovery market. Discovery of new drugs being delayed due to government regulations is a big restraint. Also, the drug market is shifting from branded to generics drugs which limit the growth of the drug discovery market in this region.

Pharmaceutical Associations:

American Association of Pharmaceutical Scientists (AAPS)

US Food and Drug Administration (FDA)

American Society for Clinical Laboratory Science (ASCLS)

National Cancer Institute Center for Cancer Research (NCI)

American Association for Clinical Chemistry (AACC)

American Society for Pharmacology and Experimental Therapeutics (ASPET)

Association of Clinical Research Organizations (ACRO)

International Pharmaceutical Manufacturers Group (IPMG)